The nation’s three dominant drug distributors and a big drugmaker have reached a $260 million deal to settle an opioid crisis lawsuit just as the first federal trial over the crisis was due to begin.
Johnson & Johnson is appealing the decision, which could be the first of many legal battles.
Both companies are under pressure to improve their performance.
Prescription drug prices have been rising over the past few years.
Pfizer hopes to run with its “little blue pill” as long as it can. That includes the time-honored strategy of launching its own generic.
Drug shortages are nothing new in U.S. hospitals.
The question is, who pays?
The European Union has some 20 "biosimilar" generics on the market; the US has one.